



Drug Quantity Management – Per Rx Sunosi™ (solriamfetol tablets) Dispensing Limit

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	2
Background.....	2
References	2
Revision History	2

Product Identifier(s)

69231

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Sunosi 75 mg and 150 mg tablets

Maximum quantity per RX = 30 tablets

Based on prescribing information, 30 of the 75 mg or 150 mg are adequate for a 30 day supply. Exceptions can be made for individuals requiring dose titration up to 150 mg daily from 75 mg daily.

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

All approvals are provided for 1 year in duration.

Sunosi 75 mg tablets

- Exceptions can be made for individuals titrating up to a dose of 150 mg daily from 75 mg daily. A one-time quantity of 60 of the 75 mg tablets may be approved.

Sunosi 150 mg tablets

- No overrides recommended.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Sunosi is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Dosing

The initial recommended dose of Sunosi in adults with narcolepsy is 75 mg once daily. The dose range for Sunosi for the treatment of narcolepsy is 75 mg to 150 mg once daily. Based on efficacy and tolerability, the dosage of Sunosi may be doubled at intervals of at least 3 days. The maximum recommended dose is 150 mg once daily. The initial recommended dose of Sunosi in adults with OSA is 37.5 mg once daily. The dosage range for Sunosi for the treatment of OSA is 37.5 mg to 150 mg once daily. Based on efficacy and tolerability, the dosage of Sunosi may be doubled at intervals of at least 3 days. The maximum recommended dosage is 150 mg once daily. Dosages above 150 mg daily do not confer increased effectiveness sufficient to outweigh dose-related adverse reactions.

For patients with moderate renal impairment (eGFR 30-59 mL/min/1.73m², the maximum recommended daily dose is 75 mg. For patients with severe renal impairment (eGFR 15-29 mL/min/1.73m² the maximum recommended daily dose is 37.5 mg. Sunosi is not recommended for use in patients with End State Renal Disease (eGFR <15 mL/min/1.73m²).

References

1. Sunosi [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; June 2019.

Revision History

Type of Revision	Summary of Changes	Date
Annual Revision	Reviewed by Clinical Specialists. No changes to criteria.	07/23/2020

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.